Education/ACR/EULAR

CT scan

SARD-ILD: Significant diagnostic and treatment delays

Gregory McDermott, MD

Should we be screening all our patients with systemic autoimmune rheumatic disease (SARD) for interstitial lung disease? I have been asking myself that question after the recent publication of American Thoracic Society Interstitial Lung Disease screening guidelines. The ATS guidelines, which

Read Article
August 29, 2025, FDA has terminated the Arthritis Advisory Committee, citing infrequent meetings & that the effort and expense of maintaining the committee “is no longer justified.” The committee last met on 5/6/21 to review avacopan - that was subsequently approved. REALLY? https://t.co/w3Z6TszeWZ
Dr. John Cush @RheumNow( View Tweet )
RheumNow Podcast – Ro, Ro, Ro52 (9.12.2025) Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.Are there benefits to diet or vegan diets? What's the effect of menopause on CTD? Ro52 makes a big entrance with all our ILD coverage this month. https://t.co/T68Cprogm3
Dr. John Cush @RheumNow( View Tweet )
Call to Update the Classification Criteria in Idiopathic Inflammatory Myopathies (IMM), Why? - EULAR/ACR myositis criteria dont cover specific myositis subtypes - Polymyositis is rare - antisynthetase & necrotizing myopathy & Jo1 Dz not well represented - Need to include MSA, https://t.co/LUfF0VCeJ7
Dr. John Cush @RheumNow( View Tweet )
My article 👇 summarizing the 2025 update of EULAR recommendations by @eular_org, presented by Josef Smolen at @APLAR_org https://t.co/QFWZmqm6IR @RheumNow #APLAR25 https://t.co/ctQdu8gQEO

Links:

Aurelie Najm @AurelieRheumo( View Tweet )

A self learning program to train non Rheumatologists to interpret pelvic X-rays and identify sacro-iliitis? It works, but it seems the participants were already well trained as pre test scores were already reaching 60+% Surprised to see radiologists constituting 1/4 of the test https://t.co/mRcFRSuAws

Links:

Aurelie Najm @AurelieRheumo( View Tweet )
yellow box among blue

SARD-ILD and serious infection risk: The elephant in the room

Jeffrey Sparks, MD, MMSc

Interstitial lung disease (ILD) remains one of the largest unmet clinical needs across many systemic autoimmune rheumatic diseases (SARD). Clinicians are already keenly aware of the complexity of patients with SARD-ILD. The “elephant in the room” for all these issues: serious infection.

Read Article
Future Perspectives of Rheumatoid Arthritis Dr. Kuni Yamaoka, shares highlights from the Future Perspectives of Rheumatoid Arthritis session at the APLAR 2025 Congress in Fukuoka, Japan. https://t.co/LGLqe48R2L https://t.co/Kwp3cFPtyw

Links:

Dr. John Cush @RheumNow( View Tweet )
lung image

When Myositis Hits the Lungs: What Every Rheumatologist Should Know About ILD

Rohit Aggarwal, MD  Shiri Keret, MD

When idiopathic inflammatory myopathies (IIM) affect the lungs, the consequences can be serious. ILD is not only common in IIM, but also one of the leading causes of death, contributing to up to 80% of mortality in this patient group. For rheumatologists, two subsets stand out: anti-synthetase

Read Article
Different B cells depletion strategies in SARDs highlighted by Georg Schett From low and short lived depletion achieved w/ drugs to sustained deep tissular depletion with CAR T cells leading to potential immune reset @RheumNow #APLAR25 https://t.co/t35lrzEomF

Links:

Aurelie Najm @AurelieRheumo( View Tweet )
Dr. Alberta Hoi graphically presents the difference bet acute confusional states & chronic cognitive changes in #lupus patients presenting with NP symptoms. NPSLE continues to pose a diagnostic challenge bec pts may present with more than one syndrome complex @RheumNow #APLAR25 https://t.co/4nYTo1fzVz

Links:

sheila @RHEUMarampa( View Tweet )
How to treat CTD ILD? A comparative slide summarizing ACR/BSR and EULAR treatment guidelines Emphasis on combination of Immunosuppressant and Antifibrotics @RheumNow #APLAR25 https://t.co/gLSht6QKh5

Links:

Aurelie Najm @AurelieRheumo( View Tweet )
“Listen to the patient, he is telling you the diagnosis”. – Sir William Osler

Dr. John Cush @RheumNow( View Tweet )

Prof. Aletaha shares their AutoPiX project - using AI to develop quantitative biomarkers. Something to look forward to since imaging remains an important diagnostic tool in #rheumatology @RheumNow #APLAR25 @rheumarhyme https://t.co/WExT9amazz

Links:

sheila @RHEUMarampa( View Tweet )
Update on Rheumatology workforce shortage in Asia-Pacific Date presented by Dr Ahmad Number of Rheumatologists per 100000 inhabitants across @APLAR_org countries -3 in Japan -1.3 in Australia, Hong Kong, Singapore -0.03 in Pakistan As a result: delayed diagnosis for patients! https://t.co/Hycqtp8BtY

Links:

Aurelie Najm @AurelieRheumo( View Tweet )
🆕 Intro to ILD (Part I): the essentials 🫁 Definition & basics 🔬 Key pathology patterns 🧑⚕️ Clinical approach 📋 What rheums need to know ⬇️ Download & learn more: https://t.co/7RzpTDOjwa Created by @MithuRheum | via @RheumNow for our Rheum to Breathe: ILD Campaign https://t.co/D9d97bqcD5

Links:

Dr. John Cush @RheumNow( View Tweet )
💥 New week, new quiz. Take 90 seconds. Prove you're the rheum news MVP. 📈 Track your accuracy 🏁 Race to the top of the leaderboard 🎯 Review what you missed Take the RheumIQ quiz ➡️ https://t.co/CASRQjoYrB https://t.co/FCjkqud0y4

Links:

Dr. John Cush @RheumNow( View Tweet )
Lessons Learned in Neuropsychiatric SLE Dr. Sheila Reyes, The Philippines, reports highlights from a session on neuropsychiatric systemic lupus erythematosus, presented at the APLAR 2025 Congress in Fukuoka, Japan. https://t.co/Dh1GQnBhvg https://t.co/wX5FgpIq7C

Links:

Dr. John Cush @RheumNow( View Tweet )
TNR: Future Treatment of ILD This Tuesday Night Rheumatology webinar reviewed ACR and EULAR guidelines on interstitial lung disease, with a focus on ‘where are we now and where are we going?’ in regards to treatment strategies and emerging therapies in ILD care. https://t.co/F1fJhWgR5O
Dr. John Cush @RheumNow( View Tweet )
Target

Hitting the Target: T2T Therapy in SLE

Sheila Reyes, MD

Treat-to-target strategies are not a new concept in rheumatology. It has shown to improve patient outcomes and quality of life in RA and PsA, and is now being increasingly adopted not only in SLE research but also in clinical practice. This article reviews key highlights from Dr. Eric Morand’s

Read Article
2025 Update of EULAR RA management recommandation Summary slide inspired from Josef Smolen’s presentation @RheumNow #APLAR25 https://t.co/wRzeX9OIry https://t.co/djrd7O9G9H

Links:

Aurelie Najm @AurelieRheumo( View Tweet )
Is it #lupus? Interesting study by @escheriKYA et al. showing comparable diagnostic performance of SLERPI (93%) in 🇵🇭 patients vs. SLICC and EULAR/ACR criteria A practical alternative tool that can be used by clinicians in a resource-limited setting 🤔 @RheumNow #APLAR25 https://t.co/xByBkjEr3r

Links:

sheila @RHEUMarampa( View Tweet )
RheumNow Podcast square

RheumNow Podcast – Ro, Ro, Ro52 (9.12.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Are there benefits to diet or vegan diets? What's the effect of menopause on CTD?  Ro52 makes a big entrance with all our ILD coverage this month.

Read Article
MTX.box

SMART study - Single vs. Split Dose Methotrexate in RA

Jack Cush, MD

Split dose weekly, oral methotrexate (MTX) was shown to be superior to single dose MTX in treating active rheumatoid arthritis (RA) patients.

Read Article
checklist on clipboard

How to assess ILD in your patients?

Janet Pope, MD, MPH, FRCPC

Have a high index of suspicion in your patients with connective tissue disease (especially systemic sclerosis, inflammatory myositis), and rheumatoid arthritis.

Read Article

Recent Blogs

From DNA to PGA

David Pisetsky, MD, PhD
dna
I have been investigating the mechanisms of antinuclear antibody (ANA) expression in SLE since 1978. In this pursuit, I have followed the advice of my first division chief, Dr. Ralph Snyderman, a great academician.  Ralph told me to identify a research focus and make it mine. I think I have done reasonably well in my mission so you can imagine my surprise (and excitement) when, for the Lupus 2025 meeting in Toronto, I was asked to conduct a Meet the Professor session on the Type 1 & 2 model for SLE. Read Post

The War Rheum

Kathryn H. Dao, M.D.
blue and yellow arms and hands
The effects on rheumatologists and their patients living in Ukraine largely have been unseen by the world. At ACR Convergence 2024, I met Dr. Marta Dzhus who practices at St. Michael's Clinical Hospital in Kyiv; she shared her story with me about the humanitarian crisis in rheumatologic care in Ukraine because of the ongoing war. Here is an excerpt of our conversation. Read Post
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×